Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM082 plus everolimus vs monotherapy in metastatic renal cell carcinoma after VEGFR-TKI failure
CTR20160987Phase 2Active
- Sponsor
- Kanangi Pharmaceutical Technology (Shanghai) Co., Ltd.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorolanib in clear cell renal cell carcinoma (ccRCC), sponsored by Kanangi Pharmaceutical Technology (Shanghai) Co., Ltd.. Started Jan 2017; status: active.
02
Drugs
vorolanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20160987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160987.